Hyperbaric Oxygen Therapy Targets Cognition in Diabetic Elderly at Dementia Risk
A completed Mount Sinai RCT tested whether HBOT can improve brain blood flow and cognition in diabetic elders with mild cognitive impairment.
Summary
Diabetes dramatically raises dementia risk, and people with both diabetes and mild cognitive impairment represent an urgent intervention target. This completed pilot randomized controlled trial from Icahn School of Medicine at Mount Sinai tested hyperbaric oxygen therapy against a sham control in 155 diabetic elderly participants with mild cognitive impairment. The trial measured changes in cognitive functioning, cerebral blood flow, and brain glucose uptake — three core mechanisms linking diabetes to neurodegeneration. HBOT delivers high-pressure oxygen to tissues, potentially reversing the vascular and metabolic deficits that accelerate brain aging in diabetics. Results from this trial, which completed in April 2024, are not yet publicly available in the abstract, but the study was designed to inform a larger multi-center investigation. If effective, HBOT could offer a non-pharmacological option to slow or reverse early cognitive decline in a high-risk population.
Detailed Summary
Dementia represents one of the most devastating and costly conditions facing aging populations worldwide. Among the strongest modifiable risk factors is type 2 diabetes, which impairs cerebral blood flow, disrupts glucose metabolism in the brain, and accelerates neurodegeneration. Identifying interventions that can arrest or reverse cognitive decline in diabetic elderly — before full dementia sets in — is a critical unmet need.
This pilot randomized controlled trial, sponsored by Icahn School of Medicine at Mount Sinai and registered under NCT03036254, enrolled 155 diabetic elderly participants diagnosed with mild cognitive impairment. Participants were randomized to either hyperbaric oxygen therapy (HBOT) or a sham intervention. HBOT involves breathing near-pure oxygen in a pressurized chamber, which dramatically increases oxygen delivery to tissues, including the brain. The trial tracked cognitive functioning, cerebral blood flow, and glucose uptake in the brain as primary outcome domains — each directly relevant to the metabolic and vascular mechanisms driving dementia in diabetic patients.
The trial completed in April 2024 after a seven-year run, suggesting a robust longitudinal follow-up design. However, results have not yet been published in peer-reviewed form, and the available abstract provides no outcome data. The study was explicitly designed as a pilot to support a future large-scale multi-center trial, indicating that its primary value may be in establishing feasibility and effect size estimates.
For clinicians managing diabetic patients with early cognitive symptoms, HBOT represents an intriguing non-pharmacological intervention grounded in plausible vascular and metabolic mechanisms. Prior smaller studies have suggested HBOT can improve cerebral perfusion and cognitive scores in aging populations, but evidence from well-powered RCTs has been lacking.
When published, results from this trial will be closely watched by both the neurology and hyperbaric medicine communities. If positive, they could establish a compelling case for HBOT as a dementia prevention strategy in high-risk diabetic populations and reshape how clinicians approach early-stage cognitive intervention.
Key Findings
- Pilot RCT tested HBOT vs. sham in 155 diabetic elderly with mild cognitive impairment over 7 years.
- Primary outcomes included cognitive function, cerebral blood flow, and brain glucose uptake.
- Trial completed April 2024; peer-reviewed results not yet publicly available.
- Designed to generate pilot data for a future large-scale multi-center HBOT dementia prevention trial.
- Addresses a critical gap: no approved interventions exist for cognitive decline in high-risk diabetic elderly.
Methodology
Pilot randomized controlled trial with 155 participants randomized to active HBOT or sham intervention, conducted at Icahn School of Medicine at Mount Sinai. The trial measured cognitive functioning, cerebral blood flow, and glucose uptake as core outcomes. Trial phase was listed as NA, consistent with a pilot feasibility design rather than a Phase II/III efficacy trial.
Study Limitations
The full trial results have not been published; this summary is based on the abstract and trial registration data only, with no outcome data available. As a pilot trial, it may be underpowered to detect definitive efficacy signals. The lack of a published protocol paper or interim results limits assessment of blinding quality, dropout rates, and outcome measurement rigor.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.